iSpecimen Strengthens Global Oncology Biospecimen Offering
December 07 2023 - 7:30AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an
online global marketplace that connects scientists requiring
biospecimens for medical research with a network of healthcare
specimen providers, announced today the addition of several new
suppliers, expanded relationships with existing suppliers and new
offerings to increase access to critically important biospecimens
for advancing biomedical research in oncology.
The expansion of the provider network offers
researchers access to specimens from cancer patients in different
treatment stages, with specific biomarkers and mutations, across
many specimen formats, including various tissue types and biofluid
formats.
“Recognizing the fact that oncology research
drives over 50 percent of the global demand for human biospecimens,
we have been working diligently to significantly expand the
iSpecimen Marketplace® by increasing access to highly-sought-after
oncology biospecimens. These specimens will be immediately
available from inventory or prospectively from target patient
populations across our global network of suppliers,” said Tracy
Curley, iSpecimen’s CEO. “What’s more, researchers will now have
access to fusion mutations and pre-screened DNA/RNA mutation
characterized tumor tissue, meeting the specific demands of their
research with enhanced precision and depth.”
In addition, the new offering supports liquid
biopsy research, which requires a high volume of specimens from
diverse patient populations. The iSpecimen Marketplace® will also
offer custom collections with peripheral blood mononuclear cells
(“PBMC”) isolation, same day whole blood collection, as well as
increased delivery offerings. To improve researcher accessibility
to iSpecimen’s virtual inventory of pre-screened mutation
characterized tumor tissue, the platform continues to utilize next
generation sequencing (“NGS”) as part of the recent cancer
sequencing procurement program.
About iSpecimeniSpecimen
(Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations
with healthcare providers that have access to patients and
specimens needed for medical discovery. Proprietary, cloud-based
technology enables scientists to intuitively search for specimens
and patients across a federated partner network of hospitals, labs,
biobanks, blood centers and other healthcare organizations. For
more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Such forward-looking statements are
characterized by future or conditional verbs such as "may," "will,"
"expect," "intend," "anticipate," “believe," "estimate" and
"continue" or similar words. You should read statements that
contain these words carefully because they discuss future
expectations and plans, which contain projections of future results
of operations or financial condition or state other forward-looking
information.
Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to the
risk factors contained in the Company's filings with the SEC, which
are available for review at www.sec.gov. Forward-looking statements
speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
statements.
Readers are cautioned not to put undue reliance
on forward-looking statements, and the Company assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information, please contact:
Investor ContactsKCSA Strategic
CommunicationsPhil Carlson / Erika Kay iSpecimen@kcsa.com
Media ContactsKCSA Strategic
CommunicationsRaquel Cona / Shana Marino iSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Apr 2023 to Apr 2024